ELU001 for Breast Cancer
Study Summary
This trial is focused on subjects with advanced, recurrent or refractory FRα overexpressing tumors. ELU001 is a new chemical entity consisting of payloads and targeting moieties covalently bound by linkers to the C'Dot particle carrier. This is the first trial of its kind and a novel molecular entity.
- Breast Cancer
- Gastric Cancer
- Esophageal Cancer
- Bile Duct Cancer
- Ovarian Tumors
- Ovarian Disease
- Endometriosis
- Cholangiocarcinoma
- Intrahepatic Cholangiocarcinoma
- Rectal Cancer
- Ovarian Metastasis
- Endometrial Cancer
- Ovarian Cancer
- Stomach Cancer
- Colon Cancer
- Colorectal Cancer
- Liver Metastasis
- Endometrial Adenocarcinoma
- Endometrial Carcinosarcoma
- Endometrioid Adenocarcinoma
- Endometrioid Tumor
- Peritoneal Neoplasm
- Gastroesophageal Junction Adenocarcinoma
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
In how many different medical clinics is this medical study being run today?
"You can find this trial at 9 locations across America, with sites in New York, Durham, and Nashville. If you want to minimize travel, it would be best to select the centre closest to your home."
How many individuals are allowed to enroll in this clinical trial?
"That is correct. The information available on clinicaltrials.gov affirms that this study, which was originally advertised on September 13th 2021, is still recruiting patients. A total of 166 people are needed for the trial taking place at 9 hospitals or clinics."
Are we still enrolling people for this experiment?
"The information on clinicaltrials.gov indicates that this study is still recruiting patients. The trial was originally posted on September 13th, 2021 and was last updated on August 18th, 2022. The study is looking for 166 patients across 9 sites."